Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.

Market News
18 May 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

ADMA Biologics is under investigation by law firm Bleichmar Fonti & Auld for potential securities fraud following a 29% stock drop. The plunge occurred after Culper Research accused the company of inflating 2025 revenue growth by 20% through channel stuffing—forcing distributors to stock excess product with rebates and extended payment terms. This allegedly masked actual demand decline, which Culper claims was a 3% revenue drop instead. Investors are encouraged to seek legal advice as class action litigation may follow.

More News (ADMA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App